Negative T790M Mutation and Met Amplification
1 clinical trials · Condition
◉ Watch Negative T790M Mutation and Met Amplification
| Record | Firm | Date |
|---|---|---|
| Glumetinib Combined With Osimertinib in the Treatment of Relapsed and Metastatic Non-small Cell Lung Cancer Patients Who Failed to Receive EGFR Inhibitors (NCT04338243) | Haihe Biopharma Co., Ltd. | 2019-11-18 |
Track Negative T790M Mutation and Met Amplification automatically
Every clearance here is in the API, with alerts when new ones post.